SAN CARLOS, Calif., Nov. 19, 2015 /PRNewswire/ — Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Jimmy Lin, MD, PhD, MHS has been appointed as Chief Scientific Officer for Oncology. Dr. Jimmy Cheng-Ho Lin joins Natera coming from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute at the National Institutes of Health. Previously, at Johns Hopkins, Dr. Lin led the computational analysis of the first ever exome sequencing studies in cancer, including breast, colorectal, pancreatic, glioblastoma, medulloblastoma, and melanoma.
In addition, Dr. Lin is the Founder and President of Rare Genomics Institute, the world’s first platform to enable any community to leverage cutting-edge biotechnology to advance understanding of any rare disease. Dr. Lin is a 2012 TED fellow and has spoken at many TED and TEDx events. He has numerous publications in Science, Nature, Cell, Nature Genetics, and Nature Biotechnology, and has been featured in multiple outlets including Forbes, Bloomberg Businessweek, Wall Street Journal, New York Times, Washington Post, the Huffington Post, and the Financial Times. Dr. Lin holds an MHS in Bioinformatics, a PhD in Cellular and Molecular Medicine, and an MD from Johns Hopkins University as well dual majors in Cognitive Science and Molecular Biophysics and Biochemistry from Yale University.
“We are pleased to announce that Jimmy Lin has joined Natera to lead our scientific research program. His contribution to the field of oncology research includes ground-breaking cancer genome sequencing efforts,” said Matthew Rabinowitz, Ph.D., CEO of Natera. “Jimmy will be driving all aspects of our oncology development program, from sample collection efforts and clinical trials, to panel design and bioinformatics.”
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum™ pre-implantation genetic test for embryo selection during IVF; the Anora™ miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama™ non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.
Mike Brophy, Investor Relations, 650-249-9091 x 1471
Michael Hromadik, Media Relations, 858-442-2215
SOURCE Natera, Inc.